Thomas Dittrich is the latest “boomerang” executive to return to a former employer as CFO. Over a decade ago he was the ...

After some six years at the post, Amgen’s finance chief is telegraphing his exit from the California pharma by early next ...

・Amgen beat Q4 estimates and struck an upbeat tone for 2026. ・A broad blockbuster lineup drove 2025 performance, with 14 products generating at least $1B each in annual sales. ・Its pipeline focuses on ...

After the drug’s local license holder called for a brief pause in new patient starts last week, doctors in Japan can once ...

Guggenheim trimmed its price target (PT) on Amgen (NASDAQ:AMGN) to $340 from $351 on Monday, May 4, while maintaining a Neutral rating. The revision follows the biotech’s Q1 2026 earnings release and ...

May 19 () - Amgen said on Tuesday its chief financial officer, Peter ‌Griffith, would retire, with Thomas Dittrich ‌taking ...

The Japanese drugmaker that sells rare-disease medicine Tavneos said new patients will be able to get the drug, which carries risk of liver injury.

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. BERLIN — In June, Amgen reported ...

View Amgen Inc. AMGN stock quote prices, financial information, real-time forecasts, and company news from CNN.

Amgen named Thomas Dittrich, a former finance executive at the company, as its next chief financial officer. The biotechnology company said Tuesday that Dittrich will succeed Peter Griffith, who is ...

The U.S. Food and Drug Administration's Center for Drug Evaluation and Research (CDER) has proposed withdrawing approval of Amgen's drug for rare autoimmune diseases, ​citing a lack of proven ...